Anti-IgE as novel therapy for the treatment of asthma

Current Opinion in Pulmonary Medicine

Volumn 5, Issue 1, 1999, Pages 76-80

  Fick Jr , Robert B ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; IMMUNOGLOBULIN E; MONOCLONAL ANTIBODY; RHUMAB E25; RHUMAB-E25;

ANIMAL; ASTHMA; CHILD; CLINICAL TRIAL; HUMAN; IMMUNOLOGY; MOUSE; REVIEW;

ALLERGENS; ANIMALS; ANTIBODIES, MONOCLONAL; ASTHMA; CHILD; CLINICAL TRIALS; HUMANS; IMMUNOGLOBULIN E; MICE;

EID: 0032600480     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-199901000-00013     Document Type: Article

References (32)

1. Centers for Disease Control National Center for Statistics: Vital and health statistics, current estimates from the National Health Interview Survey, United States, 1990. US Department of Health and Human Services, Public Health Service, 1993.
2. Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG: Association of asthma and serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989, 320:271-277.
3. Dodge RR, Burrows B: The prevalence and incidence of asthma and asthma-like symptoms in a general population sample. Am Rev Respir Dis 1980, 122:567-575.
4. Gerritsen J, Koeter GH, Postma DS, Schouten JP, Knol K: Prognosis of asthma from childhood to adulthood. Am Rev Respir Dis 1989, 140:1325-1330.
5. Kelly WJ, Hudson I, Raven J, Phelan PD, Pain MC, Olinsky A: Childhood asthma and adult lung function. Am Rev Respir Dis 1988, 138:26-30.
6. Martin AJ, Landau LI, Phelan PD: Asthma from childhood at age 21: the patient and his disease. Br Med J Clin Res Ed 1982, 284:380-382.
7. Agertoft L, Pedersen S: Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994, 88:373-381.
8. Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, et al.: Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994, 331:700-705.
9. Selroos O, Pietinalho A, Lofroos AB, Riska H: Effect of early versus late intervention with inhaled corticosteroids in Asthma. Chest 1995, 108:1228-1234.
10. Overbeek SE, Kerstjens HA, Bogaard JM, Mulder PG, Postma DS: Is delayed introduction of inhaled corticosteroids harmful in patients with obstructive airways disease (asthma and COPD)? The Dutch Chronic Nonspecific Lung Disease Study Groups. Chest 1996, 110:35-41.
11. Spahn J, Szefler S: Pharmacologic management of pediatric asthma. Immunol Allergy Clin North Am 1998, 18:165-181.
12. Martinez F, Wright A, Taussig L, Holberg C, Halonen M, Morgan W: Asthma and wheezing in the first six years of life. N Engl J Med 1995, 332:133-138.
13. National Asthma Education and Prevention Program: Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: United States Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute; 1997. [Publication no. 97-4051.] This report is the updated version of National Guidelines for the stepped-care approach to the management of asthma. Local corticosteroids are recommended for all patients with mild, persistent asthma.
14. Ishizaka K, Ishizaka T: Biological function of IgE antibodies and mechanisms of reaginic hypersensitivity. Clin Exp Immunol 1970, 6:25-31.
15. Presta LG, Shields RL, O'Connell L, Lahr S, Porter J, Gorman C, Jardieu P: The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem 1994, 269:26368-26373.
16. Shawler DL, Bartholomew RM, Smith LM, Dillman RO: Human immune response to multiple injections of murine monoclonal IgE. J Immunol 1985, 135:1530-1538.
17. Miller RA, Oseroff AR, Stratte PT, Levy R: Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 1983, 62:988-995.
18. Hakimi J, Chizzonite R, Luke DR, Familletti PC, Bailon P, Kondas JA, et al.: Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys. J Immuno 1991, 147:1352-1359.
19. Reichmann L, Clark M, Waldmann H, Winter G: Reshaping human antibodies for therapy. Nature 1988, 332:323-327.
20. Presta L, Lahr S, Shields R, Porter J, Gorman C, Fendley B, Jardieu P: Humanization of an antibody directed against IgE. J Immunol 1993, 151:2623.
21. Shields RL, Whether WR, Zioncheck K, O'Connell L, Fendly B, Presta LG, et al.: Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol 1995, 107:308-312.
22. Heusser C, Jardieu P: Therapeutic potential of anti-IgE antibodies. Curr Opin Immunol 1997, 9:805-813. A very readable review of the early studies of anti-IgE.
23. Davis EM, Gossett LA, Pinkston KI, Liou RS, Sun LK, Kirn YW, et al.: Can anti-IgE be used to treat allergy? Springer Semin Immunopathol 1993, 15:51-73.
24. Liu J, Lester P, Builder S, Shire SJ: Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 1995, 34:10474-10482.
25. Fox JA, Hotaling TE, Struble C, Ruppel J, Bates DJ, Schoenhoff MB: Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. J Pharmacol Exp Ther 1996, 279:1000-1008.
26. 20 were observed as early as 27 days after treatment began.
27. Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J, et al.: The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997, 155:1828-1834. Important work that demonstrates, for the first time, the importance of IgE to the asthmatic late-phase response.
28. Bousquet J, Demoly P: Anti-IgE therapy for asthma [editorial]. Am J Respir Crit Care Med 1997, 155:1825-1827. A balanced editorial comment on the original scientific studies by Boulet et al. (Am J Respir Crit Care Med 1997, 155:1835-1840) and Fahy et al. (Am J Respir Crit Care Med 1997, 155:1828-1834). The editorial notes the limitations of the bronchoprovocation technique while acknowledging the opportunities that are ahead for rhuMAB-E25.
29. Bousquet J, Demoly P: Anti-IgE therapy for asthma [editorial]. Am J Respir Crit Care Med 1997, 155:1825-1827. A balanced editorial comment on the original scientific studies by Boulet et al. (Am J Respir Crit Care Med 1997, 155:1835-1840) and Fahy et al. (Am J Respir Crit Care Med 1997, 155:1828-1834). The editorial notes the limitations of the bronchoprovocation technique while acknowledging the opportunities that are ahead for rhuMAB-E25.
30. Bousquet J, Demoly P: Anti-IgE therapy for asthma [editorial]. Am J Respir Crit Care Med 1997, 155:1825-1827. A balanced editorial comment on the original scientific studies by Boulet et al. (Am J Respir Crit Care Med 1997, 155:1835-1840) and Fahy et al. (Am J Respir Crit Care Med 1997, 155:1828-1834). The editorial notes the limitations of the bronchoprovocation technique while acknowledging the opportunities that are ahead for rhuMAB-E25.
31. Zeiger RS, Fick RB and E25 Study Group Investigators: Anti-IgE (rhuMAb) treatment of the symptoms of moderate-severe allergic asthma [abstract]. Ann Allergy Asthma Immunol 1998, 80:80.
32. Metzger WJ, Fick RB and the E25 Study Group Investigators: Corticosteroid (CS) withdrawal in a study of recombinant humanized monoclonal antibody to IgE (rhuMAb-E25) [abstract]. J Allergy Clin Immunol 1998, 101(suppl):231.